新华制药(000756) - 2024 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2024 was CNY 2,474,697,457.66, a decrease of 6.25% compared to CNY 2,639,665,769.78 in the same period last year[7] - Net profit attributable to shareholders was CNY 141,879,437.62, down 6.41% from CNY 151,603,818.36 year-on-year[7] - Basic earnings per share decreased by 8.70% to CNY 0.21 from CNY 0.23 in the same period last year[7] - The company reported a diluted earnings per share of CNY 0.21, down 4.55% from CNY 0.22 in the same period last year[7] - Net profit for Q1 2024 was ¥145,264,098.40, a decrease of 5.03% compared to ¥154,010,414.43 in the same period last year[34] - Earnings per share for Q1 2024 were ¥0.21, down from ¥0.23 in the previous year[34] - The total comprehensive income for Q1 2024 was ¥146,079,426.17, down from ¥161,720,238.98 in the previous year[34] Cash Flow - Net cash flow from operating activities increased by 120.72% to CNY 38,063,364.43, compared to a negative cash flow of CNY 183,742,803.27 in the previous year[7] - The increase in net cash flow from operating activities was mainly due to an increase in sales collections compared to the previous year[9] - Operating cash inflow totaled CNY 2,038,794,587.41, an increase from CNY 1,768,146,489.32 year-over-year[36] - Operating cash outflow amounted to CNY 2,000,731,222.98, compared to CNY 1,951,889,292.59 in the previous period[36] - Net cash flow from operating activities was CNY 38,063,364.43, a significant recovery from a negative CNY 183,742,803.27 last year[36] - Cash inflow from financing activities was CNY 163,552,691.73, down from CNY 659,387,232.26 in the previous year[36] - Net cash flow from financing activities was CNY 16,788,795.83, recovering from a negative CNY 56,417,414.43 last year[36] - The net increase in cash and cash equivalents was CNY 6,562,677.81, contrasting with a significant decrease of CNY 297,251,460.16 last year[37] - The ending balance of cash and cash equivalents reached CNY 788,246,932.68, up from CNY 713,512,887.35 in the previous period[37] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 8,467,977,386.18, an increase of 2.19% from CNY 8,286,166,330.90 at the end of the previous year[7] - The total assets of Shandong Xinhua Pharmaceutical Co., Ltd. reached approximately CNY 8.47 billion at the end of the reporting period, an increase from CNY 8.29 billion at the beginning of the period[21] - The company's current assets totaled approximately CNY 3.48 billion, up from CNY 3.31 billion at the beginning of the period, reflecting a growth of about 4.98%[21] - The total liabilities of the company were approximately CNY 3.48 billion, down from CNY 3.51 billion, showing a decrease of about 0.9%[24] - The company reported a total of 2,441,072,309.10 in current liabilities, a decrease from 2,486,000,478.39 at the beginning of the period, indicating a reduction of about 1.8%[24] Shareholders' Equity - Shareholders' equity attributable to the parent company increased by 4.65% to CNY 4,764,918,585.13 from CNY 4,553,103,869.56 at the end of the previous year[7] - The company's equity increased to approximately CNY 682.41 million from CNY 674.68 million, reflecting a growth of about 1.0%[24] Research and Development - Research and development expenses for Q1 2024 were ¥141,905,763.44, an increase of 26.56% from ¥112,119,587.26 in the previous year[33] Stock Options - The company adjusted the stock option incentive plan, reducing the number of incentive recipients from 196 to 194 and the number of options from 23.15 million to 22.72 million[16] - The exercise price of the stock options was adjusted from CNY 7.96 to CNY 7.61 per share[16] - The first exercise period for the stock options will allow 772,480 options to be exercised starting January 15, 2024[17] Other Income and Expenses - Non-recurring gains and losses totaled CNY 4,151,982.88 for the quarter, primarily from government subsidies and asset disposals[8] - Other income for Q1 2024 was ¥22,684,697.21, significantly higher than ¥5,670,706.38 in the previous year[33] - The company reported a decrease in tax expenses to ¥23,507,423.62 from ¥30,908,896.72 in the previous year[34]